Metastatic Melanoma Responding to Combination Chemotherapy and Immunotherapy after Progression on Ipilimumab and Nivolumab Immunotherapy

Elen Vettus, David Draper and Michael A Davies

Department of Chemotherapy, Oncology and Haematology Clinic, North Estonia Medical Center, Estonia
Department of Medical Oncology, Tri Health Cancer Institute, USA
Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, USA

^*Correspondance to: Michael A Davies 

 PDF  Full Text Case Report | Open Access

Abstract:

We report the case of a patient with stage IV M1c melanoma that developed symptomatic disease progression after treatment with combination immunotherapy (ipilimumab with nivolumab). The patient was subsequently treated with nab-paclitaxel chemotherapy and pembrolizumab and had a rapid and dramatic clinical response. The case illustrates that clinical responses are possible after progression on combination immunotherapy.

Keywords:

Metastatic melanoma; Nab-paclitaxel; Pembrolizumab; Ipilimumab; Nivolumab; Resistance

Cite the Article:

Vettus E, Draper D, Davies MA. Metastatic Melanoma Responding to Combination Chemotherapy and Immunotherapy after Progression on Ipilimumab and Nivolumab Immunotherapy. Ann Clin Case Rep. 2017; 2: 1251.